{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:32:38Z","timestamp":1759206758985,"version":"3.28.0"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Treatment sequence in primary immune thrombocytopenia (ITP) is based on national and international recommendations, treatment availability, and physician expertise.<\/jats:p><jats:p>\n          Aim\u2003This article aimed to provide real-world data on treatment sequence and responses to first- and second-line treatments in newly diagnosed and relapsed adult ITP patients.<\/jats:p><jats:p>\n          Methods\u2003We analyzed a cohort of 46 adult ITP patients from the Vienna ITP Biobank, who started first-line therapy within 1 week before their first study visit between February 2016 and March 2023. We investigated clinical patient characteristics and patient management in our specialized center and examined the impact of the international ASH guidelines on ITP treatment.<\/jats:p><jats:p>\n          Results\u2003Forty-six primary ITP patients, 27 (58.7%) with newly diagnosed ITP and 19 (41.3%) with relapsed ITP, were investigated. Most patients were female (65.2%) with a median platelet count of 9\u2009\u00d7\u2009109\/L, and 31 patients (67.4%) had bleeding symptoms. All patients received first-line treatment with oral prednisolone; 15 patients received oral prednisolone combined with intravenous immunoglobulins (IVIGs), which were more commonly administered in newly diagnosed than in relapsed ITP patients. First-line therapy resulted an overall response in 82.6% of patients after a median (interquartile range [IQR]) time of 10 (5\u201325) days. There was no difference in treatment responses between newly diagnosed and relapsed ITP patients, but newly diagnosed patients had a shorter time to response (median [IQR]: 8 [5\u201314] and 14 [8\u201327], p\u2009=\u20090.02). Twenty-three (50%) of the patients (11\/27 newly diagnosed [40.7%], 12\/19 relapsed [63.2%]) required second-line ITP therapy. Thrombopoietin-receptor agonists (TPO-RAs) were the most commonly used second-line therapy with a response rate of 73.7%, and a median (IQR) time to treatment response of 15 (12\u201320) days. Overall response rates to TPO-RA treatment did not differ between newly diagnosed and relapsed ITP. Following the publication of novel guidelines in 2019, the median (IQR) duration of corticosteroid treatment shortened (100\u201352 days, p\u2009=\u20090.01), as did the time to second-line treatment (160\u201347 days, p\u2009=\u20090.01), and the median number of first-line therapies decreased from 2 (1\u20133) to 1 (1\u20132).<\/jats:p><jats:p>\n          Conclusion\u2003Initial treatment with corticosteroids was effective in the majority of newly diagnosed and relapsed ITP. Response rates to initial corticosteroid treatment in ITP patients are consistent with previous data, but only 50% achieve sustained remission. TPO-RAs, which are well tolerated and effective, are the most commonly used second-line therapy in our study population. International guidelines have led to faster treatment transitions and reduced splenectomy rates. Integration of real-life experience, expert consensus, and guidelines optimizes ITP patient management.<\/jats:p>","DOI":"10.1055\/a-2404-0306","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T23:54:42Z","timestamp":1730850882000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria"],"prefix":"10.1055","author":[{"given":"Jasmin","family":"Rast","sequence":"first","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Schramm","sequence":"first","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Mehic","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fillitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanusch Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Drexel","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Neusiedler-Nicolas","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Gebhart","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"A Zufferey","year":"2017","journal-title":"J Clin Med"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","article-title":"Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance","volume":"80","author":"P J Ballem","year":"1987","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683416","volume-title":"Epidemiology and Clinical Manifestations of Immune Thrombocytopenia","author":"R Kohli","year":"2019"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2023.01.012","article-title":"Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia","volume":"223","author":"D Mehic","year":"2023","journal-title":"Thromb Res"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"N Cooper","year":"2021","journal-title":"Am J Hematol"},{"issue":"22","key":"ref6","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"26","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000529662","article-title":"Expert report on immune thrombocytopenia: current diagnostics and treatment - recommendations from an expert group from Austria, Germany, and Switzerland","volume":"46","author":"A Matzdorff","year":"2023","journal-title":"Oncol Res Treat"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1097\/HS9.0000000000000783","article-title":"First-line therapy for immune thrombocytopenia: time for change","volume":"6","author":"R EG Schutgens","year":"2022","journal-title":"HemaSphere"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00508-012-0123-3","article-title":"Prim\u00e4re immunthrombozytopenie des erwachsenen - Diagnostik und therapie, konsensus-statement der \u00f6sterreichischen gesellschaft f\u00fcr h\u00e4matologie und onkologie (\u00d6GHO)","volume":"124","author":"I Pabinger","year":"2012","journal-title":"Wien Klin Wochenschr"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bjh.18791","article-title":"ITP definitions: time for an update","volume":"201","author":"W Ghanima","year":"2023","journal-title":"Br J Haematol"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jha2.684","article-title":"Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States","volume":"4","author":"A Cuker","year":"2023","journal-title":"eJHaem"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.12869","article-title":"Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study","volume":"166","author":"H Frederiksen","year":"2014","journal-title":"Br J Haematol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.24702","article-title":"Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort","volume":"92","author":"G Moulis","year":"2017","journal-title":"Am J Hematol"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"e0267342","DOI":"10.1371\/journal.pone.0267342","article-title":"Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium","volume":"17","author":"A Rov\u00f3","year":"2022","journal-title":"PLoS One"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00277-002-0488-x","article-title":"Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy","volume":"81","author":"G E Pamuk","year":"2002","journal-title":"Ann Hematol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0002-9343(80)90016-9","article-title":"Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy","volume":"69","author":"S M DiFino","year":"1980","journal-title":"Am J Med"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00277-016-2665-3","article-title":"Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines","volume":"95","author":"M L Lozano","year":"2016","journal-title":"Ann Hematol"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"J N George","year":"1996","journal-title":"Blood"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V64.6.1179.1179","article-title":"Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis","volume":"64","author":"J Pizzuto","year":"1984","journal-title":"Blood"},{"issue":"11","key":"ref24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2165\/00002512-200320110-00005","article-title":"Idiopathic Thrombocytopenic Purpura A Retrospective Analysis in 139 Patients of the Influence of Age on the Response to Corticosteroids, Splenectomy and Danazol","volume":"20","author":"E Andr\u00e8s","year":"2003","journal-title":"Drugs Aging"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.24341","article-title":"Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study","volume":"91","author":"F Zaja","year":"2016","journal-title":"Am J Hematol"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"F Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-015-2556-z","article-title":"The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a \u201creal life\u201d retrospective multicenter experience of the Rete Ematologica Pugliese (REP)","volume":"95","author":"P Mazza","year":"2016","journal-title":"Ann Hematol"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"D J Kuter","year":"2019","journal-title":"Br J Haematol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12888","article-title":"The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study","volume":"165","author":"M Mah\u00e9vas","year":"2014","journal-title":"Br J Haematol"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"W Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"23","key":"ref31","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"R SM Wong","year":"2017","journal-title":"Blood"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","article-title":"Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives","volume":"101","author":"N Vianelli","year":"2022","journal-title":"Ann Hematol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.16161","article-title":"Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis","volume":"188","author":"T Puavilai","year":"2020","journal-title":"Br J Haematol"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09537104.2020.1727871","article-title":"Novel scientific approaches and future research directions in understanding ITP","volume":"31","author":"S M Hicks","year":"2020","journal-title":"Platelets"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"D Weycker","year":"2020","journal-title":"J Med Econ"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"S Pavord","year":"2020","journal-title":"Br J Haematol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"R Stasi","year":"2001","journal-title":"Blood"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"N Cooper","year":"2004","journal-title":"Br J Haematol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"A AN Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"P Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2220-z","article-title":"Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey","volume":"94","author":"A Koylu","year":"2015","journal-title":"Ann Hematol"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1002\/ajh.24310","article-title":"Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years","volume":"91","author":"F Palandri","year":"2016","journal-title":"Am J Hematol"},{"issue":"48","key":"ref43","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"L H Thai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/16078454.2021.1974203","article-title":"Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany","volume":"26","author":"O Meyer","year":"2021","journal-title":"Hematology"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2404-0306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T23:54:50Z","timestamp":1730850890000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2404-0306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1055\/a-2404-0306","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}